Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03124524
Other study ID # 2014/290
Secondary ID
Status Completed
Phase Phase 4
First received March 9, 2017
Last updated April 24, 2017
Start date January 15, 2015
Est. completion date October 10, 2016

Study information

Verified date April 2017
Source Adana Numune Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Our aim is to evaluate and compare the pain relief of estradiol valerate/dienogest and ethinylestradiol/ drospirenone by using doppler indices.

100 nullipara patients with symptoms of severe primary dysmenorrhea (PD) requesting contraception aged from 18 to 35 were included to the study. Visual analog scale (VAS), the uterine artery doppler indices including systole/diastole rates ( S/D), pulsatility index (PI) and resistance index (RI) values were evaluated and recorded in both uterine vessels before treatment. The 66 PD patients who met the inclusion criteria were divided into 2 groups and 33 healthy controls created Group 1. Group 2 were administered estradiol valerate/dienogest while Group 3 were administered 0.03 mg ethinylestradiol and 3 mg drospirenone. Both VAS scores and doppler indices were repeated after 3 months treatment. The changes in values were recorded.


Description:

This prospective, randomized, controlled clinical trial was conducted in Kayseri Education and Research Hospital, in Turkey between 2015 and 2016. Nullipara patients with symptoms of severe primary dysmenorrhea (PD) requesting contraception aged from 18 to 35 were included to the study. Afterwards, based on computer generated random numbers the patients were allocated to one of the two study arms; Group2 (Qlarista group) and Group3 (yasmin group), equally.

The PD was diagnosed clinically. The characteristic of pain was periodic (at least following 3 menstrual cycles), midline, lower abdominal cramps or pelvic colic like pain that starts up to one day before menses, lasts for the 3 days of bleeding, gradually diminishes over 12 to 72 hours and ends after period. The pain starts generally in 2 to 3 years after menarche with regular menses (25-31 day). Also absence of pelvic pathology was important in these patients for diagnosis.

Patients with history of pelvic inflammatory diseases, endometriosis, ovarian cysts, chronic abdominal pain, fibroids, obstructive endometrial polyps, cervical stenosis, inflammatory bowel syndrome, irritable bowel syndrome, major abdominal or pelvic surgery, intrauterine device and congenital obstructive müllerian malformations were excluded. Smoking, overweighted (body mass index (BMI) ≥ 30) patients that oral contraceptive pills (OCP) treatment was contraindicated were also excluded. Additionally, patients enrolled simultaneously into other studies that require drug intake or otherwise prevent compliance with protocol were out of the study.

Visual analog scale (VAS) from 0 (no pain) to 10 (maximum pain, 'worst pain I have ever felt') was applied to patients on the first day of menstrual cycle. Patients with VAS score of between 7 to10 and PD accompanied with vomiting, nausea, dizziness, headache, nervousness, diarrhea and fatigue were classified as severe PD. The ages (years), BMI (kg/m2), length of menstrual cycle (days) and length of bleeding (days) and demographic data of patients were recorded.

Before treatment during menstruation period all ultrasound examinations were carried out trans abdominally with Toshiba Xario machine ( Shimoishigami, Otawara-shi, Tochigi 324-8550, Japan) equipped with a 2.8-7 megahertz (MHz) transducer by a single radiologist (Ş.T.) The uterine artery blood flows were measured at the lateral level of uterine artery neighbour to cervicocorporeal junction in both sides (right and left). Doppler indices including systole/diastole rates ( S/D), pulsatility index (PI) and resistance index (RI) values were evaluated and recorded in both uterine vessels. Both VAS scores and doppler indices were repeated after 3 months treatment. The changes in values were recorded.

According to previously published studies and after power analyses, when α error and β error were considered, respectively, as 0.05 and 0.20, with 80% power number of patients for each group were determined as minimum 30. Power Analysis and Sample Size Software (PASS) 11 software (NCSS, Kaysville, USA) was used to perform these analyses. Regarding dropout rates (40 % -50 %) in similar studies over the treatment period we planned to include 100 patients with PD and 40 healthy controls. The PD patients who met the inclusion criteria were divided into 2 groups. Patients in Group 2 were administered estradiol valerate/dienogest (Qlarista; Bayer HealthCare Berlin, Germany). Qlarista consists of 28 tablets (including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively). Patients in Group 3 were administered 0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets) (Yasmin; Bayer HealthCare Berlin, Germany). Patients were randomly administered to the 2 treatments in a 1:1 ratio. Instead of relieving, patients were not allowed to use rescue medication (NSAI drugs) to prevent menstruation related pelvic pain.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval for the study was obtained from Erciyes University Hospital (protocol number:2014/290). Informed consent was obtained from all patients who included in our study.

All analyses were performed using the SPSS for Windows 21.0 (SPSS Inc. USA) software package. The normality of distribution for variables was assessed using the Shapiro Wilk test. Data was presented as means ± standart deviation (SD) for continuous variables. To assess the differences in variables between groups, the independent t test was used. As the results did not have a normal distribution, Kruskal-Wallis, Mann-Whitney U-test and Bonferroni correction was used in the comparisons between the groups. For comparison, the Wilcoxon test was applied to the results (VAS scores, Doppler flow parameters) before and after receiving therapy. For all comparisons, the P < 0.05 value was determined as statistically significant.


Recruitment information / eligibility

Status Completed
Enrollment 99
Est. completion date October 10, 2016
Est. primary completion date September 20, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- must be nullipara patients with symptoms of severe primary dysmenorrhea.

- The characteristic of pain must be periodic (at least following 3 menstrual cycles),

- midline,

- lower abdominal cramps or pelvic colic like pain that starts up to one day before menses,

- lasts for the 3 days of bleeding,

- gradually diminishes over 12 to 72 hours,

- ends after period.

- The pain must start generally in 2 to 3 years after menarche with regular menses (25-31 day).

Exclusion Criteria:

- Patients with history of pelvic inflammatory diseases,

- endometriosis,

- ovarian cysts,

- chronic abdominal pain,

- fibroids,

- obstructive endometrial polyps,

- cervical stenosis,

- inflammatory bowel syndrome,

- irritable bowel syndrome,

- major abdominal or pelvic surgery,

- intrauterine device,

- congenital obstructive müllerian malformations.

- patients that OCP treatment was contraindicated

- patients enrolled simultaneously into other studies that require drug intake or otherwise prevent compliance with protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
estradiol valerate/dienogest
oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
ethinylestradiol and drospirenone
oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Adana Numune Training and Research Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Doppler indices of uterine artery blood flows. Before and treatment during menstruation period the uterine artery blood flows were measured at the lateral level of uterine artery neighbour to cervicocorporeal junction in both sides (right and left). Doppler indices including systole/diastole rates ( S/D), pulsatility index (PI) and resistance index (RI) values were evaluated and recorded in both uterine vessels. up to 10 minutes
Secondary Questionnaire Questionarie: Pain relief by using Visual analog scale (VAS) before and after treatment. VAS from 0 (no pain) to 10 (maximum pain, 'worst pain I have ever felt') was applied to patients on the first day of menstrual cycle. Patients with VAS score of between 7 to10 and PD accompanied with vomiting, nausea, dizziness, headache, nervousness, diarrhea and fatigue were classified as severe PD. The ages (years), BMI (kg/m2), length of menstrual cycle (days) and lenght of bleeding (days) and demographic data of patients were recorded. up to 10 minutes
See also
  Status Clinical Trial Phase
Completed NCT03594916 - Efficacy of Transcranial Direct Current Stimulation for Severe Primary Dysmenorrhea N/A
Completed NCT03608215 - Neuromodulatary Efficacy of Transcranial Direct Current Stimulation in Severe Refractory Primary Dysmenorrhea N/A
Not yet recruiting NCT04541134 - Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea Phase 3
Completed NCT04083131 - Sense of Coherence and Primary Dysmenorrhea in High School Girls in Finistere, France
Not yet recruiting NCT05448027 - Low Versus High Intensity Laser Therapy on Primary Dysmenorrhea N/A
Completed NCT04662814 - Extracorporeal Shock Wave Therapy for Dysmenorrhea N/A
Recruiting NCT05771753 - Comparison of Core Stabilization and Dynamic Stretching Exercises in Primary Dysmenorrhea N/A
Not yet recruiting NCT04665661 - Aerobic Exercise for Primary Dysmenorrhea N/A
Completed NCT03593850 - Music for Pain in Primary Dysmenorrhea N/A
Completed NCT03290066 - Effectiveness of Kinesiotaping in Primary Dysmenorrhea N/A
Completed NCT04235595 - Comparison of the Effects of TENS and CTM on Primary Dysmenorrhea N/A
Completed NCT05081869 - Investigation of the Effect of Online Yoga Based Exercise Program on Women With Primary Dysmenorrhea N/A
Not yet recruiting NCT06398990 - The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea N/A
Completed NCT02026206 - Low-level Light Therapy for Primary Dysmenorrhea Phase 3
Completed NCT05686460 - Effect of Hegu Point Ice Massage and Music in Dysmenorrhea N/A
Not yet recruiting NCT06052722 - The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders N/A
Completed NCT04119011 - Probiotics in Women With Primary Dysmenorrhoea Phase 1/Phase 2
Active, not recruiting NCT05938660 - Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students. N/A
Completed NCT04856280 - Kinesiological Taping and Aerobic Exercise in Women With Primary Dysmenorrhea: N/A
Completed NCT02602522 - Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea Early Phase 1